Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is a biotechnology company with a promising pipeline of clinical stage programs, including its core product givastomig, which has potential as a first-in-class bispecific antibody for the treatment of gastric cancer. The company has shown notable progress in its clinical and regulatory efforts, and its current cash position provides sufficient funding to continue operations and advance its programs. Additionally, the company's "hub-and-spoke" business model provides an intriguing avenue for potential upside in the future. While there are risks associated with regulatory and development challenges, we see strong potential for NovaBridge Biosciences to continue delivering value to its shareholders.

Bears say

NovaBridge Biosciences is facing significant challenges in the biotechnology market, with uncertainties surrounding the efficacy of its core product, givastomig, and concerns about its ability to compete with other anti-VEGF competitors. Additionally, regulatory, commercial, clinical development, and manufacturing risks could impact the company's growth potential. The recent acquisition of VIS-101 and Bridge Health assets could provide some support, but a lower headcount and increased costs suggest potential struggles in the near future.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.